HK1211464A1 - Gel containing pirfenidone - Google Patents

Gel containing pirfenidone

Info

Publication number
HK1211464A1
HK1211464A1 HK15112082.7A HK15112082A HK1211464A1 HK 1211464 A1 HK1211464 A1 HK 1211464A1 HK 15112082 A HK15112082 A HK 15112082A HK 1211464 A1 HK1211464 A1 HK 1211464A1
Authority
HK
Hong Kong
Prior art keywords
gel containing
containing pirfenidone
pirfenidone
gel
Prior art date
Application number
HK15112082.7A
Other languages
English (en)
Chinese (zh)
Inventor
喬斯‧
‧馬加納卡斯特羅
勞拉‧瓦斯克斯塞萬提斯
胡安‧
‧阿門達里茲博倫達
Original Assignee
Cell Therapy And Technology S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40350871&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1211464(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cell Therapy And Technology S A De C V filed Critical Cell Therapy And Technology S A De C V
Publication of HK1211464A1 publication Critical patent/HK1211464A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
HK15112082.7A 2007-08-14 2010-10-28 Gel containing pirfenidone HK1211464A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2007009796A MX2007009796A (es) 2007-08-14 2007-08-14 Gel conteniendo pirfenidona.

Publications (1)

Publication Number Publication Date
HK1211464A1 true HK1211464A1 (en) 2016-05-27

Family

ID=40350871

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15112082.7A HK1211464A1 (en) 2007-08-14 2010-10-28 Gel containing pirfenidone

Country Status (14)

Country Link
US (5) US8492412B2 (xx)
EP (1) EP2177220B1 (xx)
JP (1) JP5542053B2 (xx)
KR (1) KR101235968B1 (xx)
CN (2) CN101808641A (xx)
BR (1) BRPI0815203B8 (xx)
CA (1) CA2696335C (xx)
CO (1) CO6180448A2 (xx)
EC (1) ECSP109960A (xx)
HK (1) HK1211464A1 (xx)
MX (1) MX2007009796A (xx)
SG (1) SG183732A1 (xx)
WO (1) WO2009022899A1 (xx)
ZA (1) ZA201000918B (xx)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
EP2296653B1 (en) 2008-06-03 2016-01-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
CN101972225A (zh) * 2010-10-13 2011-02-16 北京诚创康韵医药科技有限公司 一种含吡非尼酮的凝胶组合物
JP6021117B2 (ja) 2011-01-31 2016-11-02 ジェノア ファーマシューティカルズ，インク． エアロゾルのピルフェニドンおよびピリドンアナログの化合物、および、その使用
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
EP3091976A4 (en) 2014-01-10 2017-10-11 Genoa Pharmaceuticals Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
US10233195B2 (en) 2014-04-02 2019-03-19 Intermune, Inc. Anti-fibrotic pyridinones
MX366086B (es) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1049411A (en) 1972-12-18 1979-02-27 Affiliated Medical Research N-substituted pyridone and general method for preparing pyridones
ES421598A1 (es) 1972-12-18 1977-01-01 Affiliated Med Res Un procedimiento para la sintesis de piridonas.
US4042699A (en) 1972-12-18 1977-08-16 Affiliated Medical Research, Inc. Method for reducing serum glucose levels
US3839346A (en) 1972-12-18 1974-10-01 Affiliated Med Res N-substituted pyridone and general method for preparing pyridones
US4052509A (en) 1972-12-18 1977-10-04 Affiliated Medical Research, Inc. Method for reducing serum uric acid levels
ZA757570B (en) * 1974-12-09 1977-07-27 Affiliated Med Res A useful n-substituted pyridone
US4105782A (en) 1975-03-07 1978-08-08 Yu Ruey J Treatment of acne and dandruff
JPS51128438A (en) 1975-04-26 1976-11-09 Yamanouchi Pharmaceut Co Ltd An antibacterial drug against fish diseases
SE430609B (sv) 1976-12-21 1983-11-28 Sca Development Ab Sett att ur cellulosaderivat framstella absorberande material
US4376118A (en) * 1980-10-06 1983-03-08 Miles Laboratories, Inc. Stable nonaqueous solution of tetracycline salt
JPS60214732A (ja) * 1984-04-05 1985-10-28 Grelan Pharmaceut Co Ltd 外用貼付剤
JP2618256B2 (ja) * 1988-03-31 1997-06-11 ポーラ化成工業株式会社 消炎鎮痛外用剤
US5310562A (en) * 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions
US5716632A (en) * 1989-11-22 1998-02-10 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
US5009895A (en) 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
EP0702551B1 (en) 1993-05-07 2002-09-25 MARGOLIN, Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
US5436241A (en) * 1994-01-14 1995-07-25 Bristol-Myers Squibb Company Topical anti-inflammatory compositions containing piroxicam
UA56151C2 (uk) * 1995-12-21 2003-05-15 Пфайзер, Інк. Водний ін'єкційний розчин данофлоксацину (варіанти) та спосіб лікування бактеріальних інфекцій
DE19639816A1 (de) * 1996-09-27 1998-04-02 Hoechst Ag Antimykotische Mittel mit hoher Wirkstofffreisetzung
US5958420A (en) * 1997-03-13 1999-09-28 Nortrade Medical, Inc. Treatment of burns, cuts, and abrasions of the skin
US6365131B1 (en) * 1997-10-31 2002-04-02 J. B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical dental formulation for topical application of metronidazole benzoate, chlorhexidine gluconate and local anesthetic
CA2322994A1 (en) 1998-03-17 1999-09-23 Solomon B. Margolin Topical antiseptic compositions and methods
GB9810949D0 (en) 1998-05-22 1998-07-22 Hewlett Healthcare Limited Formulation
US6492395B1 (en) 1998-09-18 2002-12-10 Mepha Ag Topical formulation of alkyl-, phenyl-pyridone
US20020028784A1 (en) 2000-03-10 2002-03-07 Nest Gary Van Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
IN191090B (xx) * 2000-08-29 2003-09-20 Ranbanx Lab Ltd
KR100777169B1 (ko) 2001-01-29 2007-11-16 시오노기세이야쿠가부시키가이샤 5-메틸-1-페닐-2-(1ｈ)-피리돈을 활성 성분으로서함유하는 의약 제제
WO2003030720A2 (en) 2001-10-09 2003-04-17 The Children's Hospital Of Philadelphia Materials and methods for preventing or reducing scar formation
CH696420A5 (de) 2002-09-13 2007-06-15 Mepha Ag Neue stabile Zubereitungen von Alkyl-, Phenyl-Pyridonen für topische Anwendung.
JP4542743B2 (ja) * 2002-12-26 2010-09-15 Ｋｄｌ株式会社 ピリドン誘導体の溶液状医薬組成物
TW200501952A (en) * 2003-02-21 2005-01-16 Shionogi & Co Pirfenidone gel formulations
AU2003225670A1 (en) 2003-02-28 2004-09-28 Intermune, Inc. Interferon drug therapy for the treatment of viral diseases and liver fibrosis
AU2003299962A1 (en) 2003-02-28 2004-09-28 Intermune, Inc. Interferon drug therapy for the treatment of viral diseases and liver fibrosis
WO2004089283A2 (en) 2003-04-04 2004-10-21 Intermune, Inc. Compositions and methods for treating viral infections
EP1638625A4 (en) 2003-05-23 2009-08-19 David M Ott ORGANOSOUFRES PROMEDICAMENTS FOR PREVENTING AND TREATING INFECTIOUS DISEASES AND A PATHOLOGICAL REACTION OF THE IMMUNE SYSTEM
WO2005000227A2 (en) 2003-06-06 2005-01-06 Intermune, Inc. Methods of treating tnf-mediated disorders
RS20110578A3 (en) 2003-10-14 2016-02-29 F. Hoffmann-La Roche Ltd MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULPHONAMIDES AS HCV REPLICATION INHIBITORS
US7491794B2 (en) 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
WO2005040758A2 (en) 2003-10-24 2005-05-06 Intermune, Inc. Use of pirfenidone in therapeutic regimens
US20070258946A1 (en) 2003-12-23 2007-11-08 Blatt Lawrence M Combination Therapy for Treating Hepatitis C Virus Infection
CN100542532C (zh) 2004-05-24 2009-09-23 上海睿星基因技术有限公司 吡非尼酮在制备治疗肝损伤坏死和急性肺损伤的药物中的用途
US20060051339A1 (en) 2004-09-08 2006-03-09 Sivak Hannah N Composition for treatment of oily skin and acne prevention and methods of making and using same
US20060115503A1 (en) 2004-11-30 2006-06-01 Goyal Muna C Composition, system and method for treatment of skin
ES2524922T3 (es) 2005-05-10 2014-12-15 Intermune, Inc. Derivados de piridona para modular el sistema de proteína cinasa activada por estrés
US20090148407A1 (en) 2005-07-25 2009-06-11 Intermune, Inc. Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication
NZ591443A (en) 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
EP2426134A3 (en) 2005-11-23 2012-07-04 Intermune, Inc. Method of modulating stress-activated protein kinase system
US8586078B2 (en) * 2005-12-05 2013-11-19 Rba Pharma Inc. Emulsion-containing medical articles
CN101088557A (zh) 2006-06-12 2007-12-19 天津市扶素生物技术有限公司 用于预防或治疗hiv感染的药用组合物及其应用
CA2676906A1 (en) 2007-02-12 2008-08-21 Intermune, Inc. Novel inhibitors hepatitis c virus replication
US20100069319A1 (en) 2007-03-02 2010-03-18 Talia Miron Mercaptopurine derivatives and uses thereof
US20080287508A1 (en) 2007-05-18 2008-11-20 Intermune, Inc. Altering pharmacokinetics of pirfenidone therapy
US8383823B2 (en) 2007-06-20 2013-02-26 Auspex Pharmaceuticals Substituted N-aryl pyridinones
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
US20090137354A1 (en) 2007-11-27 2009-05-28 Shimano Inc. Bicycle rear derailleur
EP2628747A1 (en) 2007-12-11 2013-08-21 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
US20100256031A1 (en) 2008-10-10 2010-10-07 Jeffrey Wu Shine control cleanser
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
CN101972225A (zh) 2010-10-13 2011-02-16 北京诚创康韵医药科技有限公司 一种含吡非尼酮的凝胶组合物
CN101972236A (zh) 2010-10-13 2011-02-16 北京诚创康韵医药科技有限公司 一种含吡非尼酮的缓释制剂
JP6021117B2 (ja) 2011-01-31 2016-11-02 ジェノア ファーマシューティカルズ，インク． エアロゾルのピルフェニドンおよびピリドンアナログの化合物、および、その使用
CN107007546A (zh) 2011-02-15 2017-08-04 阿勒根公司 用于治疗红斑痤疮的症状的羟甲唑啉药物乳膏组合物
CN102670600A (zh) 2011-03-12 2012-09-19 赵海静 一种抑制瘢痕和促进创口愈合的医药产品,其制备方法和应用
CN102670632A (zh) 2011-03-12 2012-09-19 赵海静 吡非尼酮在抑制皮肤瘢痕形成的医药用途
US9241921B2 (en) 2011-05-02 2016-01-26 Pankaj Modi Photosensitizer composition for treating skin disorders
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
CN102488660A (zh) 2011-12-15 2012-06-13 西安天一秦昆制药有限责任公司 一种含吡非尼酮的缓释微丸
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
WO2013181691A1 (en) 2012-06-04 2013-12-12 The Macfarlane Burnet Institute For Medical Research And Public Health Ltd A method of treatment and compositions useful therefor, screening and prognostic agents and uses therefor
KR20150037822A (ko) 2012-06-12 2015-04-08 에프. 호프만-라 로슈 아게 Ｈｃｖ 감염을 치료하기 위한 치료제의 조합물
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
CA2819967C (en) 2012-08-31 2016-03-22 Intermune, Inc. Use of pirfenidone concomitantly with ciprofloxacin
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
US9156896B2 (en) 2013-03-15 2015-10-13 Coda Therapeutics, Inc. Wound healing compositions and treatments
EP2968572A1 (en) 2013-03-15 2016-01-20 Medicis Pharmaceutical Corporation Topical compositions of flunisolide and methods of treatment
MX352342B (es) 2013-07-12 2017-11-22 Moleculas Naturales S A De C V Star Un procedimiento para fabricar un complejo mejorado de cloruro de bencetonio-dialil oxido de disulfuro modificado, el complejo obtenido y sus usos.
CN103550242B (zh) 2013-11-22 2015-07-15 四川国康药业有限公司 一种治疗肝纤维化的药物组合物及其制备方法
GB201508419D0 (en) 2015-05-15 2015-07-01 Cambridge Entpr Ltd Detection of T cell exhaustion or lack of T cell costimulation and uses thereof
WO2017104725A1 (ja) 2015-12-16 2017-06-22 第一三共株式会社 創傷治療剤
JOP20170113B1 (ar) 2016-05-09 2023-03-28 Bayer Pharma AG مركبات 5، 6، 7، 8-رباعي هيدرو [1، 2، 4] تريازولو [4، 3-أ] بيريدين 3(2h)-ون مستبدلة ومركبات 2، 5، 6، 7-رباعي هيدرو-3h-بيرولو [2، 1-ج] [1، 2، 4] تريازول-3-ون واستخداماتها
MX364040B (es) 2016-11-11 2019-04-11 Cell Therapy And Tech S A De C V Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash).
TWI770157B (zh) 2017-04-10 2022-07-11 德商拜耳廠股份有限公司 經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途
MX366086B (es) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.
MX368750B (es) 2018-08-31 2019-10-15 Cell Therapy And Tech S A De C V Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular.
EP4135671A1 (en) 2020-04-14 2023-02-22 Excalibur Pharmaceuticals, Inc. Pirfenidone for coronavirus treatment

Also Published As

Publication number Publication date
EP2177220B1 (en) 2019-05-29
MX2007009796A (es) 2009-02-25
BRPI0815203B8 (pt) 2021-05-25
US11083719B2 (en) 2021-08-10
ECSP109960A (es) 2010-04-30
KR101235968B1 (ko) 2013-02-21
US20130245073A1 (en) 2013-09-19
WO2009022899A8 (es) 2009-09-11
US20170216268A1 (en) 2017-08-03
EP2177220A1 (en) 2010-04-21
US20200016138A1 (en) 2020-01-16
US11779574B2 (en) 2023-10-10
US20220016096A1 (en) 2022-01-20
JP2010536747A (ja) 2010-12-02
CN104771355A (zh) 2015-07-15
CA2696335C (en) 2014-03-04
EP2177220A4 (en) 2013-09-11
CA2696335A1 (en) 2009-02-19
KR20100040319A (ko) 2010-04-19
WO2009022899A1 (es) 2009-02-19
US20110224265A1 (en) 2011-09-15
BRPI0815203A2 (pt) 2017-03-28
JP5542053B2 (ja) 2014-07-09
BRPI0815203B1 (pt) 2020-05-05
ZA201000918B (en) 2011-04-28
CO6180448A2 (es) 2010-07-19
SG183732A1 (en) 2012-09-27
CN101808641A (zh) 2010-08-18
US8492412B2 (en) 2013-07-23
US10376500B2 (en) 2019-08-13

Similar Documents

Publication Publication Date Title
HK1211464A1 (en) Gel containing pirfenidone
GB0700580D0 (en) Use
ZA200909137B (en) Applicator
GB0712503D0 (en) Use
GB0714670D0 (en) Use
GB0703328D0 (en) Gel forming compounds
GB0801211D0 (en) Enclosures
GB0721332D0 (en) Medicaments
GB0719518D0 (en) Therapy
GB0706787D0 (en) Novel use
EP2223811A4 (en) APPLICATOR
GB0705264D0 (en) Gel forming compounds
GB0709528D0 (en) Enclosure
PL2027842T3 (pl) Chłonny wyrób
IL183496A0 (en) Single use sinkstainer
GB0723519D0 (en) Novel use
GB0723523D0 (en) Novel use
GB0721333D0 (en) Medicaments
GB2449333B (en) Appetite-control aid
GB2449050B (en) Shoping aid
GB0701096D0 (en) Use
GB0716072D0 (en) Therapy
GB0700635D0 (en) Therapy
GB0723723D0 (en) Use
GB0708021D0 (en) Use